Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY12 | Q9H244 | 3/20 | 0.43 |
| ▸ | GAPDH | P04406 | 2/20 | 0.43 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.41 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.41 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.41 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.41 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.41 |
| ▸ | DNPH1 | O43598 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30448663 | 1.00 | P2RY12 (0.43) | P2RY12GAPDHP2RY2P2RY1P2RY6 | |
| SCHEMBL26347734 | 0.86 | GAPDH (0.41) | P2RY12GAPDHP2RY2P2RY1P2RY6 | |
| SCHEMBL30448759 | 0.86 | GAPDH (0.41) | P2RY12GAPDHP2RY2P2RY1P2RY6 | |
| SCHEMBL30580422 | 0.86 | P2RY12 (0.46) | P2RY12P2RY2P2RY1P2RY6ADORA2A | |
| SCHEMBL26347769 | 0.86 | GAPDH (0.43) | P2RY12GAPDHP2RY2P2RY1P2RY6 | |
| SCHEMBL14102400 | 0.82 | P2RY12 (0.47) | P2RY12P2RY2P2RY1P2RY6ADORA2A | |
| SCHEMBL3320975 | 0.82 | P2RY12 (0.47) | P2RY12P2RY2P2RY1P2RY6ADORA2A | |
| SCHEMBL3320995 | 0.82 | P2RY12 (0.47) | P2RY12P2RY2P2RY1P2RY6ADORA2A | |
| SCHEMBL13396790 | 0.80 | P2RY12 (0.45) | P2RY12P2RY2P2RY1P2RY6ADORA2A | |
| SCHEMBL26347749 | 0.80 | GAPDH (0.38) | P2RY12GAPDHP2RY2P2RY1P2RY6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230303613-A1 | 3′3′ CYCLIC DINUCLEOTIDES WITH AN ALKENYLENE | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY AS CR, V.V.I. (CZ) | 2023-09-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230303613-A1 | 3′3′ CYCLIC DINUCLEOTIDES WITH AN ALKENYLENE | STING1, CGAS, IRF3 | P2RY12 39/4885GAPDH 2262/4885P2RY2 24/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.